NCT04545710: Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Active, not recruiting | 2 | 18 | US | Abemaciclib, Verzenios, Osimertinib, Tagrisso | University of California, San Diego, Eli Lilly and Company | Lung Cancer | 12/25 | 12/26 | | |